Wintermute is Now Recruiting Patients for the ZosterEase Phase Ib Clinical Trial. Read more here.
Understanding how Solexan™ works against viruses is a crucial step in bringing it to medical clinics and helping people with herpes infections.
Wintermute Biomedical is very excited to share our latest publication on the antiviral properties of Solexan™ (GS-1), a novel formulation that shows promise in blocking the entry of herpes viruses and other enveloped viruses. Varicella-Zoster Virus (VZV) and Herpes Simplex Virus (HSV), which infect over 66% of the population, cause diseases like chickenpox, shingles, and oral and genital herpes.
Current antiviral treatments face limitations, including the need for early intervention and the development of drug resistance, especially in immunocompromised patients. While shingles vaccines exist, their use is limited by availability, access, awareness, and cost, and there is no vaccine for HSV. Our study demonstrates the potential of GS-1 as a topical antiviral agent, offering a new therapeutic strategy for managing Varicella-Zoster Virus (VZV) and Herpes Simplex Virus (HSV) infections. The unique mechanism of GS-1, which involves preventing viral entry into host cells, could significantly enhance the effectiveness of current antiviral treatments.
A huge thank you to all our collaborators involved in this project, especially La Trobe Institue for Molecular Science (LIMS). We are excited to follow the journey of Solexan to treating clinics!
To find out more about our publication, click here.
And to find out more about our ZosterEase clinical trial into shingles, click here.